Medical and Pharmaceutical InMed Pharmaceuticals publicizes new peer-reviewed study New academic journal spotlights potential for rare cannabinoids to treat skin conditions Rowan DunneJune 20, 2022
Business InMed Pharma rolls out rare cannabinoid via BayMedica D9-THCV one of many in company cannabinoid portfolio set to diversify and expand in coming years Rowan DunneJune 13, 2022
Business InMed Pharmaceuticals reports net loss of US$10.2M The firm says expenses will increase as research and 'important progress' continues Kathryn TindaleSeptember 24, 2021
The weed wire Preclinical results for InMed’s CBN glaucoma treatment show promise Studies showed CBN formulations reduced interocular pressure and protected retinal cells in the eye Nick LabaMay 27, 2020
Medical and Pharmaceutical Cannabinol (CBN) the main ingredient in potential treatments for glaucoma and a rare skin disease InMed Pharmaceuticals has initiated a clinical trial for its epidermolysis bullosa treatment, after regulatory approval in December Nick LabaJanuary 20, 2020